You are here

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment
  1. Timothy R Sterling
  1. A2209 Medical Center North, Nashville, Tennessee, USA
  1. Correspondence to : Dr Timothy Sterling, A2209 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232, USA; timothy.sterling{at}vanderbilt.edu

https://doi.org/10.1136/ebmed-2014-110139

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Study 1: Gillespie SH, Crook AM, McHugh TD, et al; REMoxTB Consortium. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371:1577–87.OpenUrlCrossRefPubMedWeb of Science

    Study 2: Merle CS, Fielding K, Sow OB, et al; OFLOTUB/Gatifloxacin for Tuberculosis Project. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371:1588–98.OpenUrlCrossRefPubMedWeb of Science

    Study 3: Jindani A, Harrison TS, Nunn AJ, et al; RIFAQUIN Trial Team. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371:1599–608.OpenUrlCrossRefPubMedWeb of Science

    Context

    Current antituberculosis therapy is …

    View Full Text

    Footnotes

    • Competing interests TS serves on a data safety monitoring board for a clinical trial sponsored by Otsuka.

    • Provenance and peer review Commissioned; internally peer reviewed.